Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium longum 1714
- Development stage
- Preclinical
- Lead developer
- Novones
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium longum 1714 is a specific strain of probiotic bacteria, also known as a psychobiotic, that has been studied for its effects on the gut-brain axis. [12] Developed by PrecisionBiotics in partnership with the APC Microbiome Institute in Cork, Ireland, this strain has been shown to support mental well-being by modulating the body's response to stress. [2, 8] Clinical studies have indicated that B. longum 1714 can reduce perceived stress and cortisol levels, improve cognitive function, and enhance sleep quality. [4, 9, 15] Its mechanism of action involves immunomodulation, such as reducing pro-inflammatory cytokines like TNF-alpha and increasing the anti-inflammatory cytokine IL-10, and influencing tryptophan metabolism, a precursor to serotonin and melatonin. [11, 13] It is commercially available as a dietary supplement under brand names like Zenflore and ProbioBrain. [1, 7]
- Brand names
- ZenfloreZenflore CalmProbioBrainMindAble 1714MindAble1714MindAble-1714Just Calm
- Other names
- Bifidobacterium longum 1714 Serenitas
02
Targets
IL10 (Interleukin-10)TNFA (Tumor necrosis factor alpha (soluble))IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on Bifidobacterium longum 1714.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium longum 1714.